Vor Biopharma (VOR) Stock Price, News & Analysis

Company Overview

Vor Biopharma, Inc. is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Preclinical studies have demonstrated selective resistance of edited HSCs to CD33-directed therapies, allowing concurrent administration of anti-CD33 agents to eliminate malignant cells while preserving healthy hematopoiesis. In addition to VOR33, Vor maintains a discovery pipeline of follow-on candidates targeting other hematologic cancer antigens, as well as programs exploring combination strategies with existing immunotherapies.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vor Biopharma went public in 2021 and collaborates with leading academic medical centers and contract development organizations across the United States. The company is led by President and Chief Executive Officer Sean Nolan, whose previous experience includes senior leadership roles in immuno-oncology and cell therapy development. Vor’s scientific advisory board comprises experts in hematology, stem cell biology, and genome editing, supporting its mission to transform the treatment paradigm for blood cancer patients.

Key Stats

• Today's Range: $31.50 to $33.17
• 50-Day Range: $27.24 to $48.72
• 52-Week Range: $2.62 to $65.80
• Volume: 291,413 shs
• Average Volume: 480,606 shs
• Market Capitalization: $221.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $113.83
• Consensus Rating: Hold

Vor Biopharma Stock Analysis - MarketRank™

Vor Biopharma scored higher than 63% of companies evaluated by MarketBeat, and ranked 6th out of 22 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Vor Biopharma has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 5 buy ratings, 5 hold ratings, and 1 sell rating.

Upside Potential

Vor Biopharma has a consensus price target of $113.83, representing about 252.5% upside from its current price of $32.29.

Amount of Analyst Coverage

Vor Biopharma has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Vor Biopharma is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vor Biopharma is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

27.92% of the float of Vor Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Vor Biopharma has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vor Biopharma has recently decreased by 94.44%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vor Biopharma does not currently pay a dividend.

Dividend Growth

Vor Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

27.92% of the float of Vor Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Vor Biopharma has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vor Biopharma has recently decreased by 94.44%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.44

News Sentiment

Vor Biopharma has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.42 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Vor Biopharma this week, compared to 4 articles on an average week.

Search Interest

26 people have searched for VOR on MarketBeat in the last 30 days. This is an increase of 117% compared to the previous 30 days.

MarketBeat Follows

4 people have added Vor Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vor Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,890,146.00 in company stock.

Percentage Held by Insiders

Only 0.45% of the stock of Vor Biopharma is held by insiders.

Percentage Held by Institutions

97.29% of the stock of Vor Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VOR Stock Analysis - Frequently Asked Questions

How have VOR shares performed this year?

Vor Biopharma's stock was trading at $21.20 at the beginning of 2025. Since then, VOR shares have increased by 52.3% and is now trading at $32.29.

How were Vor Biopharma's earnings last quarter?

Vor Biopharma Inc. (NASDAQ:VOR) issued its quarterly earnings results on Tuesday, August, 12th. The company reported ($43.60) EPS for the quarter, missing the consensus estimate of ($11.40) by $32.20.

When did Vor Biopharma's stock split?

Vor Biopharma shares reverse split on the morning of Thursday, September 18th 2025.The 1-20 reverse split was announced on Thursday, September 18th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 18th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Vor Biopharma IPO?

Vor Biopharma (VOR) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel acted as the underwriters for the IPO.

How do I buy shares of Vor Biopharma?

Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Biological Products, Except Diagnostic Substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VOR
• Previous Symbol: NASDAQ:VOR
• CIK: 1817229
• Web: N/A
• Phone: (617) 655-6580
• Fax: N/A
• Employees: 140
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Vor Biopharma: $113.83
• High Price Target: $280.00
• Low Price Target: $8.00
• Potential Upside/Downside: +252.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.36
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 6,850,000
• Free Float: 6,823,000
• Market Cap: $221.19 million
• Optionable: N/A
• Beta: 2.07